VABIOTECH licenses cell-based japanese encephalitis technology from Inviragen
The Company for Vaccine and Biological Production No.1 (VABIOTECH) and Inviragen, Inc. announced a licensing agreement by which VABIOTECH will acquire rights to Inviragen’s proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine.
A cell-based JE vaccine has the potential to offer improved manufacturing consistency and safety due to the reduced contaminant, preservatives and unnecessary excipients present compared to the previous generation of animal-derived JE vaccines. Under the terms of the agreement, VABIOTECH may exclusively develop and commercialize JE vaccine based on this technology in Vietnam, Cambodia and Myanmar. In exchange, Inviragen will receive certain development-based milestone payments from VABIOTECH.
“The technology licensed from Inviragen will help advance our JE vaccine production technology,” commented Professor Dr. Nguyen Thu Van, director general of the Company. "In partnership with the Ministry of Health, we have made great strides to control the spread of JE infection in Vietnam. We look forward to incorporating this vaccine technology from Inviragen into our JE program."
Other news from the department research and development
